Skip to main content
Premium Trial:

Request an Annual Quote

Agilent to Market, Sell ExonHit SpliceArrays Worldwide

NEW YORK, May 31 (GenomeWeb News) - Agilent Technologies will market and sell ExonHit's line of splice variant arrays as commercial products worldwide, the companies said today.   


Agilent will now offer nine different ExonHit human and mouse SpliceArrays through its offices globally.


ExonHit's SpliceArray technology "also complements [Agilent's existing] portfolio of microarray-based research tools," Fran Dinuzzo, Agilent's vice president and general manager of integrated biology solutions, said in a statement.


Agilent originally agreed to distribute ExonHit's arrays last August. The arrays were initially offered only through a service when they were launched by ExonHit in February 2005.


Financial details of the new alliance were not discussed.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.